Edition:
United States

Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

69.46USD
15 Oct 2018
Change (% chg)

-- (--)
Prev Close
$69.46
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,698,673
52-wk High
$72.89
52-wk Low
$52.83

Latest Key Developments (Source: Significant Developments)

IMV Announces Early Positive Results From Phase 2 Clinical Trial Of Lead Candidate DPX-Survivac In Combination With Merck’S Keytruda In Patients With DLBCL
Tuesday, 18 Sep 2018 07:05am EDT 

Sept 18 (Reuters) - Imv Inc ::IMV INC. ANNOUNCES EARLY POSITIVE RESULTS FROM PHASE 2 CLINICAL TRIAL OF LEAD CANDIDATE DPX-SURVIVAC IN COMBINATION WITH MERCK’S KEYTRUDA® IN PATIENTS WITH DLBCL.IMV INC - DATA SHOWED TWO OF FIRST FOUR EVALUABLE PARTICIPANTS SHOWED TUMOR REGRESSIONS AT FIRST ON-TREATMENT CT SCAN.IMV INC - IN TRIAL, COMBINATION THERAPY APPEARS TO DEMONSTRATE AN ACCEPTABLE SAFETY PROFILE, WITH NO SERIOUS ADVERSE EVENTS REPORTED TO DATE.IMV INC - FIRST ENROLLED PARTICIPANT DEMONSTRATED A TUMOR REGRESSION OF 48% AT FIRST ON-TREATMENT SCAN.IMV INC - SECOND PARTICIPANT DEMONSTRATED A PARTIAL RESPONSE (PR) VIA A TUMOR REGRESSION OF 66% AT FIRST ON-TREATMENT SCAN.IMV INC - PRELIMINARY DATA FROM THIRD PARTICIPANT IN TRIAL OF DPX-SURVIVAC IN COMBINATION WITH KEYTRUDA DEMONSTRATED STABLE DISEASE.IMV INC - FOURTH PARTICIPANT HAD EARLY DISEASE PROGRESSION LESS THAN TWO MONTHS FOLLOWING TREATMENT INITIATION AND WAS DISCONTINUED FROM STUDY.  Full Article

Accenture And Merck Collaborate With Amazon Web Services To Launch A Research Platform To Drive Innovation In Drug Discovery And Scientific Research
Monday, 17 Sep 2018 08:29am EDT 

Sept 17 (Reuters) - Accenture PLC ::ACCENTURE AND MERCK COLLABORATE WITH AMAZON WEB SERVICES TO LAUNCH A RESEARCH PLATFORM TO DRIVE INNOVATION IN DRUG DISCOVERY AND SCIENTIFIC RESEARCH.ACCENTURE PLC - MERCK IS COLLABORATING WITH ACCENTURE ON LAUNCH AND WILL BE FIRST PHARMACEUTICAL COMPANY TO USE PLATFORM.ACCENTURE PLC - NEW RESEARCH PLATFORM IS BEING DEVELOPED BY MERCK AND ACCENTURE.ACCENTURE PLC - PLATFORM WILL ALLOW RESEARCHERS TO QUICKLY AGGREGATE, ACCESS AND ANALYZE RESEARCH DATA FROM MULTIPLE APPLICATIONS.ACCENTURE PLC - PLATFORM IS BUILT ON AWS.  Full Article

Merck Canada Says Some Lots Of MARVELON28 Distributed In Canada Do Not Contain Day-Of-The-Week Label Stickers
Tuesday, 11 Sep 2018 12:04pm EDT 

Sept 11 (Reuters) - Merck Canada Inc::MERCK CANADA SAYS NOTIFIED HEALTH CARE PROFESSIONALS OF IMPORTANT INFORMATION ON MARVELON28 (DESOGESTREL/ETHINYL ESTRADIOL) ORAL CONTRACEPTIVE TABLETS.MERCK CANADA SAYS NOTIFIED HEALTH CARE PROFESSIONALS THAT SOME LOTS OF MARVELON28 DISTRIBUTED IN CANADA DO NOT CONTAIN DAY-OF-THE-WEEK LABEL STICKERS.MERCK CANADA SAYS ARE NOT DISTRIBUTING MARVELON28 UNTIL CO CAN START ONCE AGAIN DELIVERING PRODUCT THAT CONTAIN DAY-OF-THE-WEEK LABEL STICKERS.  Full Article

Health Canada Approves Merck's Stromectol (Ivermectin) For The Treatment Of Intestinal Strongyloidiasis And Onchocerciasis
Tuesday, 11 Sep 2018 07:00am EDT 

Sept 11 (Reuters) - Merck & Co Inc ::HEALTH CANADA APPROVES MERCK'S STROMECTOL (IVERMECTIN) FOR THE TREATMENT OF INTESTINAL STRONGYLOIDIASIS AND ONCHOCERCIASIS.MERCK CANADA - STROMECTOL'S AVAILABILITY IS EXPECTED IN NOVEMBER 2018.  Full Article

U.S. FDA Updates Prescribing Information For Keytruda & Tecentriq
Thursday, 16 Aug 2018 06:31pm EDT 

Aug 16 (Reuters) - U.S. Food and Drug Administration::FDA - UPDATES PRESCRIBING INFORMATION FOR KEYTRUDA (PEMBROLIZUMAB) & TECENTRIQ (ATEZOLIZUMAB) TO REQUIRE USE OF FDA-APPROVED COMPANION DIAGNOSTIC TEST.FDA SAYS TWO COMPANION DIAGNOSTIC TESTS APPROVED; ONE FOR USE WITH KEYTRUDA & ONE FOR TECENTRIQ.FDA - SECOND-LINE INDICATIONS IN UROTHELIAL CARCINOMA FOR KEYTRUDA (PEMBROLIZUMAB) & TECENTRIQ (ATEZOLIZUMAB) REMAIN UNCHANGED.FDA - UPDATED PRESCRIBING INFORMATION FOR KEYTRUDA & TECENTRIQ TO REQUIRE USE OF APPROVED TEST FOR SELECTION OF PATIENTS WHO ARE CISPLATIN-INELIGIBLE.  Full Article

Eisai And Merck Announce FDA Grants Breakthrough Therapy Designation
Tuesday, 31 Jul 2018 06:30am EDT 

July 31 (Reuters) - Merck & Co Inc ::EISAI AND MERCK ANNOUNCE FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION FOR LENVIMA® (LENVATINIB) IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) AS THERAPY FOR PREVIOUSLY TREATED PATIENTS WITH ADVANCED AND/OR METASTATIC NON-MSI-H/PMMR ENDOMETRIAL CARCINOMA.  Full Article

Viralytics Says Federal Court Of Australia Approved Scheme Of Arrangement
Sunday, 3 Jun 2018 10:16pm EDT 

June 4 (Reuters) - Viralytics Ltd ::FEDERAL COURT OF AUSTRALIA APPROVES SCHEME OF ARRANGEMENT.SCHEME, UPON IMPLEMENTATION, WILL RESULT IN MERCK SHARP & DOHME (HOLDINGS) PTY BUYING ALL SHARES IN CO.  Full Article

Oncosec Expands Relationship With Merck For Combination Of Immunopulse Il-12 And Keytruda
Tuesday, 8 May 2018 07:30am EDT 

May 8 (Reuters) - OncoSec Medical Inc ::ONCOSEC EXPANDS RELATIONSHIP WITH MERCK, ANNOUNCES CLINICAL COLLABORATION TO EVALUATE COMBINATION OF IMMUNOPULSE IL-12 AND KEYTRUDA FOR TRIPLE NEGATIVE BREAST CANCER.ONCOSEC MEDICAL - PLANNED TRIAL WILL EVALUATE SAFETY, EFFICACY OF COMBINATION IN CERTAIN PATIENTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC TNBC.ONCOSEC MEDICAL SAYS UNDER COLLABORATION AGREEMENT, ONCOSEC WILL SPONSOR, FUND STUDY AND MERCK WILL PROVIDE KEYTRUDA.ONCOSEC MEDICAL SAYS ADDITIONAL DETAILS OF THE COLLABORATION WERE NOT DISCLOSED.  Full Article

Keytruda Monotherapy Met Primary Endpoint In Phase 3 Study, Significantly Improving OS As First-Line Therapy In Locally Advanced Or Metastatic NSCLC Patients Expressing PD-L1 In At Least 1 Pct O
Monday, 9 Apr 2018 06:45am EDT 

April 9 (Reuters) - Merck & Co Inc ::KEYTRUDA® (PEMBROLIZUMAB) MONOTHERAPY MET PRIMARY ENDPOINT IN PHASE 3 KEYNOTE-042 STUDY, SIGNIFICANTLY IMPROVING OS AS FIRST-LINE THERAPY IN LOCALLY ADVANCED OR METASTATIC NSCLC PATIENTS EXPRESSING PD-L1 IN AT LEAST 1 PERCENT OF TUMOR CELLS.SAFETY PROFILE OF KEYTRUDA IN PHASE 3 TRIAL WAS CONSISTENT.PHASE 3 KEYNOTE-042 TRIAL WILL CONTINUE TO EVALUATE PROGRESSION-FREE SURVIVAL (PFS), WHICH IS A SECONDARY ENDPOINT.  Full Article

Incyte, Merck Provide Update On Phase 3 Study
Friday, 6 Apr 2018 07:30am EDT 

April 6 (Reuters) - Incyte Corp ::INCYTE AND MERCK PROVIDE UPDATE ON PHASE 3 STUDY OF EPACADOSTAT IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) IN PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA.INCYTE AND MERCK PROVIDE UPDATE ON PHASE 3 STUDY OF EPACADOSTAT IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) IN PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA.STUDY'S SECOND PRIMARY ENDPOINT OF OVERALL SURVIVAL ALSO IS NOT EXPECTED TO REACH STATISTICAL SIGNIFICANCE.BASED ON RESULTS, AND AT RECOMMENDATION OF EDMC, PHASE 3 STUDY WILL BE STOPPED.252 WAS CONSISTENT WITH THAT OBSERVED IN STUDIES OF EPACADOSTAT IN COMBINATION WITH KEYTRUDA.252 STUDY EVALUATING EPACADOSTAT WITH KEYTRUDA DETERMINED STUDY DID NOT MEET PRIMARY ENDPOINT.  Full Article

Cancer center CEO leaves Merck board after disclosure scandal

NEW YORK The chief executive of Memorial Sloan Kettering Cancer Center, Craig Thompson, resigned from the boards of drugmaker Merck & Co Inc and lab services firm Charles River Laboratories International Inc on Tuesday, following media investigations about the U.S. center's ties to the pharmaceutical industry.